When was Candel Therapeutics founded?

Candel Therapeutics was founded in 1999.

Where is Candel Therapeutics located?

Candel Therapeutics is headquartered in United States.

Who is the current CEO of Candel Therapeutics?

Aguilar Estuardo of Candel Therapeutics.

How many employees does Candel Therapeutics have?

As of Jul 31, 2026, the latest employee count at Candel Therapeutics is 91.

Is Candel Therapeutics a funded company?

Candel Therapeutics is a funded company, having raised a total of $81.6M across 14 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of Candel Therapeutics?

Candel Therapeutics' latest funding was a $***** Series C round on Apr 01, 2019, with participation from 2 investors.

What is the annual revenue of Candel Therapeutics?

Annual revenue of Candel Therapeutics is less than $1M as on Dec 31, 2022

Where does Candel Therapeutics rank among its competitors?

Candel Therapeutics ranks 26th amongst 428 active competitors, of which 161 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Vyriad, which secured $25M in Dec, 2025.

Who are the top competitors of Candel Therapeutics?

Candel Therapeutics' top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, Vyriad secured the most recent funding round in December, 2025.

Candel Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Candel Therapeutics is a public company based in United States, founded in 1999. It operates as a Developer of viral immunotherapies for the treatment of cancer. Candel Therapeutics has raised $81.6M in funding from PBM Capital. The company has 428 active competitors, including 161 funded and 94 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.

Company Details

Developer of viral immunotherapies for the treatment of cancer. The company is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms.

Website: candeltx.com
Social
Email ID: *****@candeltx.com

Key Metrics

Founded Year

1999

Location

United States

Stage

Public

Total Funding

$81.6M in 14 rounds

Latest Funding Round

Series C, Apr 01, 2019, $*****

Investors

PBM Capital & 5 more

Ranked

26^th among 428 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2022

Employee Count

91 as on Jul 31, 2026

Similar Companies

Abcellera Biologics & 558 more

Exit Details

Public

View Candel Therapeutics' full profile

Candel Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CANDEL THERAPEUTICS, INC. CIN: 1841387 , United States, Active	Jun 05, 2003	$0 - $1M (As on Dec 31, 2022)	-	-
Candel Therapeutics, Inc CIN: 001-40629 , United States, Active	Dec 31, 2017	-	76 (As on Dec 31, 2022)	-

Candel Therapeutics got listed on Jul 27, 2021.

Click here to take a look at Candel Therapeutics's IPO in detail

Candel Therapeutics has raised a total funding of $81.6M over 14 rounds. Its latest funding round was a Series C round on Apr 01, 2019 for $*****. 2 investors participated in its latest round. Candel Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Candel Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2019	4441150	Series C	4984350	9090953	9413368	9082348
Jan 04, 2019	8319951	Series B	7400243	6678405	8034253	7908497
Sep 12, 2016	3638384	Unattributed	5265196	8876539	2900815	3939288

Access funding benchmarks and valuations. Sign up today!

View details of Candel Therapeutics's funding rounds and investors

Candel Therapeutics' employee count trend

Candel Therapeutics has 91 employees as of Jul 26. Here is Candel Therapeutics's employee count trend over the years:

Employee count trend for Candel Therapeutics

Uncover Candel Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Candel Therapeutics include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Candel Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, RA Capital Management & 9 others	70/100
4th	Replimune 2015, Oxford (United Kingdom), Public	Developer of oncolytic immunotherapies	$87M	Foresite Capital, Omega Funds & 7 others	67/100
5th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	66/100
6th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Nextech Invest & 19 others	65/100
7th	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
8th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
9th	Vyriad 2016, Rochester (United States), Series B	Developer of oncolytic-virus-based immunotherapies for cancer treatment	$125M	Mayo Clinic Ventures, Southeast Minnesota Capital Fund ... & 7 others	63/100
10th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
26th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, Northpond Ventures & 4 others	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Candel Therapeutics's competitors? Click here to see the top ones

Candel Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Candel Therapeutics's sector:

Free

Oncology - Sector Report

Edition: July, 2026 (74 Pages)

View all reports related to Candel Therapeutics

Media has covered Candel Therapeutics for a total of 28 events in the last 1 year, 18 of them have been about company updates and 2 about people movement.